N	Concordance
1	 l response rate of patients with adult medulloblastoma, peripheral primitive ne
2	ntral nervous system neoplasms, such as medulloblastoma, and some skin cancers. 
3	eveloped hindlimb defects or cerebellar medulloblastomas, abnormalities also see
4	sive genomic abnormalities in childhood medulloblastoma by comparative genomic h
5	ulloblastomas, and 2 of 17 desmoplastic medulloblastomas. The sequence changes i
6	 to 47 years) who underwent surgery for medulloblastoma at a single center betwe
7	athologically confirmed posterior fossa medulloblastoma (CCG diagnosis code  204
8	n, growth, and viability of a new human medulloblastoma cell line (UM-MB1).     
9	 greater degree of genomic imbalance in medulloblastoma than has been recognized
10	tanding of the role of neurotrophins in medulloblastomas, especially the ability
11	nd DNA content, suggest that lipomatous medulloblastoma is to be considered as a
12	?  Like most brain tumours the cause of medulloblastoma is unknown. Researchcont
13	uld establish whether the occurrence of medulloblastoma in an FAP family represe
14	n therapy in the treatment of pediatric medulloblastoma/primitive neuroectoderma
15	 the body after birth. For this reason, medulloblastomas are sometimes called pr
16	 outcome for patients with average-risk medulloblastoma.[17] However, trials a